Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Exploring the clinical manifestations and penetrance of a French-Canadian founder mutation in the fumarate hydratase gene, FH
FY 2022-23
Summary
Renal cancer (RCC) is the 7th most diagnosed cancer in men and 12th in women in Canada. Certain genetic syndromes predispose individuals to developing RCC. One example is hereditary leiomyomatosis and renal cell carcinoma (HLRCC), which occurs when a gene called fumarate hydratase (FH) is mutated. Among those born with this genetic mutation, approximately 15% will develop RCC which often spreads to other organs, resulting in death, unless it is detected at an early stage.
Unusual pinkish rubbery skin tumors, called cutaneous leiomyomas, are often the first sign of this syndrome, leading patients to consult a dermatologist who can make the diagnosis of HLRCC and refer for renal cancer screening. Uterine fibroids in women are also commonly found in HLRCC. In 2007, Dr. Foulkes’ team published the case of a 17-year-old French-Canadian who died of advanced RCC. A specific FH gene variant was found in his family which was subsequently found in multiple other patients. Interestingly, all patients are of French-Canadian (FC) origin, which suggests a common ancestor (founder effect). Recently his team has identified another likely founder mutation in FH in the FC population. Our study consists of a review of medical charts of all patients with HLRCC identified at the McGill-associated hospitals to understand this disease and its associated cancers. We will describe the spectrum of clinical manifestations with a focus on the severity of skin lesion and risk of renal cancer. . Laboratory work will also allow us to estimate the frequency of this variant in the general French-Canadian population (not affected by cancer) and better understand its origin. Ultimately, this project will help achieve a greater knowledge of the genetics of inherited RCC
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486118
Name
Ouchene Lydia
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring the clinical manifestations and penetrance of a French-Canadian founder mutation in the fumarate hydratase gene, FH
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cutaneous Leiomyoma; Founder Mutation; Genodermatoses; Hereditary Cancer; Oncogenetics; Papillary Renal Cancer Type 2; Reed Syndrome; Renal Cancer; Uterine Leiomyoma
Abstract
Renal cancer (RCC) is the 7th most diagnosed cancer in men and 12th in women in Canada. Certain genetic syndromes predispose individuals to developing RCC. One example is hereditary leiomyomatosis and renal cell carcinoma (HLRCC), which occurs when a gene called fumarate hydratase (FH) is mutated. Among those born with this genetic mutation, approximately 15% will develop RCC which often spreads to other organs, resulting in death, unless it is detected at an early stage.
Unusual pinkish rubbery skin tumors, called cutaneous leiomyomas, are often the first sign of this syndrome, leading patients to consult a dermatologist who can make the diagnosis of HLRCC and refer for renal cancer screening. Uterine fibroids in women are also commonly found in HLRCC. In 2007, Dr. Foulkes’ team published the case of a 17-year-old French-Canadian who died of advanced RCC. A specific FH gene variant was found in his family which was subsequently found in multiple other patients. Interestingly, all patients are of French-Canadian (FC) origin, which suggests a common ancestor (founder effect). Recently his team has identified another likely founder mutation in FH in the FC population. Our study consists of a review of medical charts of all patients with HLRCC identified at the McGill-associated hospitals to understand this disease and its associated cancers. We will describe the spectrum of clinical manifestations with a focus on the severity of skin lesion and risk of renal cancer. . Laboratory work will also allow us to estimate the frequency of this variant in the general French-Canadian population (not affected by cancer) and better understand its origin. Ultimately, this project will help achieve a greater knowledge of the genetics of inherited RCC
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ouchene, Lydia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~